Farimah Masoumi

Prof. Farimah Masoumi

Tonekabon Azad University of Medical Sciences
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PMPeiman Brouki Milan
Peiman Brouki Milan
FMFarimah Masoumi
Farimah Masoumi
EBEsmaeil Biazar
Esmaeil Biazar
SJSaeedeh Zare Jalise
Saeedeh Zare Jalise
AMArezou Mehrabi
Arezou Mehrabi

18 September 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FMFarimah Masoumi
Farimah Masoumi
SSSofia Mendes Saraiva
Sofia Mendes Saraiva
Belén L BouzoBelén L Bouzo
Belén L Bouzo
RLRafael López-López
Rafael López-López
MEManel Esteller
Manel Esteller
MFMaria De la Fuente
Maria De la Fuente
Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53-mediated DNA damage and the intracellular localization of the oncogenic YBX1 protein. However, to translate this finding into the clinic as a gene therapy, it is important to develop effective carriers able to deliver exogenous lncRNAs to the targeted cancer cells. Here, we propose the use of biocompatible sphingomyelin nanosystems comprising DOTAP (DSNs) to carry and deliver a plasmid vector encoding for TP53TG1 (pc(TP53TG1)-DSNs) to a colorectal cancer cell line (HCT-116). DSNs presented a high association capacity and convenient physicochemical properties. In addition, pc(TP53TG1)-DSNs showed anti-tumor activities in vitro, specifically a decrease in the proliferation rate, a diminished colony-forming capacity, and hampered migration and invasiveness of the treated cancer cells. Consequently, the proposed strategy displays a high potential as a therapeutic approach for colorectal cancer.

19 August 2022 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
MAMaryam Azimi
Maryam Azimi
SSSanaz Keshavarz Shahbaz
Sanaz Keshavarz Shahbaz
AMAmir Hossein Mansourabadi
Amir Hossein Mansourabadi
LKLeila Mohamed Khosroshahi
Leila Mohamed Khosroshahi
SPShahryar Pourkalhor
Shahryar Pourkalhor
FMFarimah Masoumi
Farimah Masoumi
The human colon harbors a diverse array of microorganisms that play fundamental roles in colorectal cancer (CRC). Increasing evidence indicates that dysbiosis of the intestinal microbiome has been associated with the development of CRC. Interaction between host genetics, intestinal microbiota, and lifestyle is well-indicated in the influence, prevention, and treatment of CRC. Various microbiome compositions have reported anticancer and/or anti-inflammatory properties. The presence of our microbiota is integral to our development, but a change in its composition can often lead to adverse effects, increasing the propensity for serious diseases like cancers. Recently, molecular detection and metabolomic techniques have increased our knowledge of the role of microbiota in promoting tumorigenesis. Dietary interventions may be appropriate to regulate the growth of beneficial microbiota in the gut. Metagenomic approaches along with immunology and metabolomics will obvious a new path for the treatment of CRC. In this study, we summarized recent advances in understanding the mechanisms involved in microbiota-related colorectal carcinoma, based on evidence from immunotherapy studies.